Kevzara is an interlukin-6 receptor antibody, which is used for treating adult patients with moderate to severe
stages of active rheumatoid arthritis (RA) who have shown indecisive response or intolerance to one or more
non-biologic or biologic DMARDs i.e. Disease Modifying Anti Rheumatic Drugs. The development of new drugs
which help to treat this diseases more effectively called biologics, or disease modifying agents. The increasing
elderly population worldwide and approval of new drugs for treating various rheumatic diseases, the growing
awareness among society about the treatment of rheumatic diseases and lucrative environment of the
treatment has driven the growth of the market. Additionally high funding for research and development
activities is likely to boost the growth of the market.
Segments Covered
The report on global rheumatology therapeutics market covers segments such as drug class, disease
indication, and distribution channel. The drug class segments include disease modifying anti-rheumatic drugs,
nonsteroidal anti-inflammatory drugs, corticosteroids, uric acid drugs and others. On the basis of disease
indication the global rheumatology therapeutics market is categorized into rheumatoid arthritis,
osteoarthritis, gout, psoriatic arthritis, ankylosing spondylitis and others. Furthermore, on the basis of
distribution channel the rheumatology therapeutics market is segmented as hospital pharmacy, retail
pharmacy and online pharmacy.
Make an Enquiry
https://www.infiniumglobalresearch.com/reports/enquiry/1129
Geographic Coverage
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and
Rest of the World. In this section the key trends and market size for each geography is provided over the
period of 2016 – 2024. The countries covered in the North America region include the U.S., Canada, and
Mexico; while Asia-Pacific includes China, Japan, India, South Korea and Malaysia among others. The U.S.
Infinium Global Research